🔬 Siphtor← Home
EngineSiphtor Multi-Agent Research Pipeline
CoverageGlobal Macro / Trade Telemetry / Corporate Filings
Run Duration3m 28s
StatusLive Autonomous Briefing

Siphtor Research

Merck KGaA Raises 2026 Guidance After Strong Q3

Merck KGaA increased its 2026 sales guidance to €21.5-21.9 billion, after a third quarter that exceeded expectations, signaling continued strong performance fuelled by demand for AI chip materials and pharmaceutical manufacturing products. This is the third time the company has raised its full-year outlook, demonstrating a sustained upward trajectory.

By Siphtor Media

Published: 11/16/2026

Merck KGaA Raises 2026 Guidance After Strong Q3

Merck KGaA increased its 2026 sales guidance to €21.5-21.9 billion, after a third quarter that exceeded expectations, signaling continued strong performance fuelled by demand for AI chip materials and pharmaceutical manufacturing products. This is the third time the company has raised its full-year outlook, demonstrating a sustained upward trajectory.

Revenue for the quarter rose nearly 6% year-over-year to €5.63 billion, with the Life Science and Electronics divisions leading the growth. The Electronics division benefited significantly from the ongoing boom in artificial intelligence, with high demand for Merck’s products used in advanced chip architectures. The boost in AI-related materials is a key driver, as management expressed confidence that the AI trend will persist, citing substantial development potential. However, this positive performance is partially offset by increased competition impacting its multiple sclerosis drug, Mavenclad, in the US market.

The company now anticipates an adjusted EBITDA of €6.2 to €6.4 billion for 2026, up from a previous forecast of €5.9 to €6.3 billion. This increase reflects both improved operational performance and favorable currency effects. The guidance also incorporates a contribution from the recent acquisition of Bio-Techne, expected to close by year-end, which will bolster Merck’s Life Science business. Though Mavenclad revenue is expected to decline sharply in the US due to generic competition, the company has been adjusting its expectations for this decline over the course of the year.

The raised guidance and strong quarterly results come amidst a broader positive trend in the Indian banking and finance sector, suggesting a generally favorable economic climate for companies like Merck. However, the company anticipates a stronger revenue decrease in the final quarter for chip materials used in consumer electronics due to rising memory chip prices impacting consumer spending, presenting a potential headwind. The company’s ability to navigate this dynamic—leveraging AI demand while managing the slowdown in consumer electronics—will be critical to sustaining its growth momentum.

XETR_MERCK_KGAAXETR_MERCK_KGAA • Corporate Filing Telemetry
Open & Model This Dataset in Siphtor AI

Enjoyed this article?

Siphtor Media subscribers get unlimited articles, interactive charts, and the full economic data dashboard — starting at $7.99/month.

Free newsletter · No spam · Unsubscribe anytime

Keep Exploring